Latest From Gritstone Oncology
Public Company Edition: ORIC’s initial public offering is the third by a drug developer in April and the 12th in 2020. Also, Pluristem garnered €50m from the European Investment Bank.
Advances in multiple scientific areas will mature into novel therapeutics, often tailored for the individual patient and increasingly curative, making biopharma an exciting place to be in 2020.
Immuno-oncology development trends are revealed through an analysis of deals between cancer drug developers over the past five years.
Public Company Edition: Trevi Therapeutics was the first out of the gate on 7 May, but four more biopharma firms went public in the US on 8 May, while just 13 IPOs launched between January and April. Also, new financings include debt for BMS, Bausch and Intercept.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- North America
- Company Type
- Parent & Subsidiaries
- Gritstone Oncology
- Senior Management
Andrew Allen, MD, PhD, Pres. & CEO
Jean-Marc Bellemin, EVP, CFO
Matthew Hawryluk, PhD, EVP, CBO
Karin Jooss , PhD, EVP, Research & CSO
Roman Yelensky, PhD, EVP, CTO
Raphael F Rousseau, MD, PhD, EVP, CMO
Vijay Yabannavar, PhD, EVP, Mfctng. & Tech. Operations
- Contact Info
Phone: (510) 871-6100
5858 Horton St.
Emeryville, CA 94608